AMG 355 vs Azirkitug

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: CCR8 · full Non-Small Cell Lung Cancer pipeline

AMG 355

Developed by Amgen

monoclonal antibody
Weak signal

NCT06131398 · Phase 1 · completed

Everyone in the study knowingly received AMG 355, with no random assignment and no comparison group, so there is no way to separate the drug's effect from natural variation between patients. No results have been posted yet.

No aligned efficacy figure on record for this race.

Azirkitug

Developed by AbbVie

Phase 1 in Non-Small Cell Lung Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: July 2027 · NCT05005403 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAMG 355Azirkitug
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported—Not reported
Duration of response, median—Not reported—Not reported

PFS, median

AMG 355
—Not reported
Azirkitug
—Not reported

OS, median

AMG 355
—Not reported
Azirkitug
—Not reported

ORR

AMG 355
—Not reported
Azirkitug
—Not reported

Duration of response, median

AMG 355
—Not reported
Azirkitug
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

AMG 355: no structured comparison results are available for Non-Small Cell Lung Cancer.

Azirkitug: no structured comparison results are available for Non-Small Cell Lung Cancer.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AMG 355's landscape · Azirkitug's landscape